In the battle against blood cancer, chimeric antigen receptor T cell (CAR-T) therapy is proving to be a shining light on the horizon. Dr Allen…

Special Report: A form of immunotherapy that involves modifying a patient’s white blood cells so they recognise and target cancer cells is shaping up as…

Today, we will acquaint you with the product pipeline of ASX-listed clinical-stage biotechnology company Prescient Therapeutics Limited (ASX:PTX). Prescient Therapeutics is gaining attention for its remarkable progress…

StockTalk is a Stockhead video series featuring a roundtable of experts discussing a new investment topic each week. In this edition, host Dr Nigel Finch discusses ASX…

When local synthetic antibiotics developer Recce Pharmaceuticals announced they had entered into an antiviral Sars-CoV-2 screening program in partnership with the CSIRO and the University…

Biotech Prescient Therapeutics (ASX: PTX) has successfully raised $7 million to fund an expanded pipeline of innovative cancer treatments. The clinical stage oncology company today…

Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the pen and picking up the microphone for another instalment of The Health Kick…

Prescient Therapeutics (ASX: PTX) Chief Executive Officer Steven Yatomi-Clarke joins Small Caps to discuss the company’s novel approach to treating cancer using targeted and cellular…

Locally-listed small cap biotech company Prescient Therapeutics hopes to shift the conversation around cancer from treatments to cures, as it invests in a new-age technology showing early…

ASX-listed clinical-stage company Prescient Therapeutics Limited (ASX:PTX) is well-known for developing breakthrough targeted and personalised medicines approaches for the treatment of challenging cancer. On 14 August 2020,…